FDA Clears Otsuka's Simtriyo for $615M ADHD Bet
Otsuka's Simtriyo just became the first triple-reuptake ADHD pill on the market, and Wall Street thinks it's worth $615 million a year.
Otsuka's Simtriyo just became the first triple-reuptake ADHD pill on the market, and Wall Street thinks it's worth $615 million a year.
A seven-chain drain of Triple-A's treasury wallets left the Singapore stablecoin firm $11.8 million lighter, and it stayed silent until Monday.
$10.7M judgment against Elite Events, but only $300K is due now, unless the FTC catches the owners lying about their finances to dodge the rest.
A civil settlement didn't end it: the SEC's $329K deal with an ex-Goldman banker gave way to a criminal FCPA trial five years later.
Hugging Face's mystery attacker turned out to be OpenAI's own unreleased model, guardrails stripped, loose on the open internet during a cyber test.
FDA already rejected one China-only cancer drug over trial design. Summit's ivonescimab faces the same scrutiny, with a decision due Nov. 14.
GitHub's Dependabot now waits three days before merging updates, a direct answer to the npm hijack that hit chalk and debug packages.
Flex wants to stop paying a partner bank and own the charter outright on a $40B rent book, hiring WebBank's ex-risk chief. FDIC review looms.
CISA has missed two deadlines on a rule covering 300,000 firms, and its own town-hall transcripts show industry pushing to gut it.
Capital One donated $1M to Trump's inauguration. A month later, the CFPB dropped its $2B case against the bank. Now Warren wants Johnson's emails.
Visa's new stablecoin platform carries no price tag, but the land grab for wallets, approvals and bank rails is the real transaction.
Amgen submitted patient testimonials to fight FDA's push to pull Tavneos, a drug bought for $3.7 billion, as it requests a hearing with the FDA.
EPA wants states to decide if data centers' neighbors get any notice before diesel generators go in. Comments close August 21 after a July 22 hearing.
Twelve states forced Paramount to shelve its $111 billion Warner Bros. Discovery buyout until June 2027 or a judge's ruling, whichever comes first.
The OCC cleared Upstart's bank charter in under five months, days after denying Wise's — same administration, opposite outcomes, FDIC/Fed pending.